Vir Biotechnology, Inc. — Director's Dealing 2019

Oct 10, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2019-10-10

Reporting Person: TLS Beta Pte. Ltd. (10% Owner)
Reporting Person: Temasek Life Sciences Private Ltd (10% Owner)
Reporting Person: Fullerton Management Pte Ltd (10% Owner)
Reporting Person: Temasek Holdings (Private) Ltd (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$		Common Stock (3333333)		Indirect
Series B Preferred Stock	$		Common Stock (1666666)		Indirect

Footnotes

F1: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2: The securities reported herein are directly held by TLS Beta Pte. Ltd, which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.